BioSpace News Archive

Medtronic plc, the global leader in medical technology, announced the launch of the Prevail™ drug coated balloon Catheter in Europe following CE mark.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that management will present at two upcoming virtual investor conferences:

Aadi Bioscience, Inc., a privately-held, clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced that the U.S. Food and Drug Administration has accepted the company’s New Drug Application for its nanoparticle albumin-bound mTOR inhibitor, FYARRO™ and has granted the company Priority Review status with a Prescription Drug User Fee Act target action date of November 26, 2021.

Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced that it will release its financial results for the second quarter and six months ended June 30, 2021, after the close of market on Monday, Aug. 9, 2021.

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for a Phase 1 study evaluating the company’s lead asset, NT-I7, a novel long-acting human interleukin-7, for the treatment of Kaposi Sarcoma in patients with or without infection with HIV.

Virios Therapeutics, Inc., a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic pain and fatigue related diseases, announced that all 41 sites involved in its ongoing 460 patient Phase 2b fibromyalgia trial are now fully activated and enrolling patients.

Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase of 4,629,630 shares of its common stock at a purchase price per share of $2.70, in a private placement priced at-the-market under Nasdaq rules.

IVERIC bio, Inc. (Nasdaq: ISEE) today announced the early completion of patient enrollment of GATHER2, the Company’s second pivotal clinical trial of Zimura® (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Catalyst Pharmaceuticals, Inc. today announced that it will release second quarter 2021 financial results after market close on Monday, August 9, 2021.

F-star Therapeutics, Inc. is providing an interim update on the first-in-human dose-escalation study of SB 11285, a second generation STING agonist.